Something went wrong with the connection!

Pneumococcal Infections Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

 Breaking News
  • No posts were found

Pneumococcal Infections Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

May 10
20:03 2023
Pneumococcal Infections Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 15+ key pharma and biotech companies are working on 20+ pipeline drugs in the Pneumococcal Infections therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Pneumococcal Infections Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Pneumococcal Infections Market. 

The Pneumococcal Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Pneumococcal Infections Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Pneumococcal Infections and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Pneumococcal Infections market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Pneumococcal Infections Pipeline Analysis

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Pneumococcal infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intranasal

  • Intrathecal

  • Intravenous

  • Oral

  • Oral/Intravenous

  • Parenteral

  • Subcutaneous

  • Subcutaneous/Intramuscular

  • Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

  • Antisense oligonucleotide

  • Gene therapy

  • Hormones

  • Neuropeptides

  • Oligonucleotides

  • Small Molecule

  • Triglyceride

Learn How the Ongoing Clinical & Commercial Activities will Affect the Pneumococcal Infections Therapeutic Segment @

Pneumococcal Infections Therapeutics Landscape

There are approx. 15+ key companies developing therapies for Pneumococcal infections. Currently, Affinivax is leading the therapeutics market with its Pneumococcal infections drug candidates in the most advanced stage of clinical development.

The Leading Players in the Pneumococcal Infections Therapeutics Market Include:

  • Affinivax

  • Astellas Pharma

  • Beijing Zhifei Lvzhu Biopharmaceutical

  • CanSino Biologics Inc.

  • EuBiologics

  • Gangagen

  • GlaxoSmithKline

  • ImmunoBiology

  • LG Life Sciences

  • Merck Sharp & Dohme

  • Panacea Biotech

  • Pfizer

  • SK Chemicals Co., Ltd.

  • SutroVax

  • Vaxcyte

And Many Others

Pneumococcal Infections Emerging and Marketed Drugs Covered in the Report Include:

ASP3772: Affinivax

  • ASP3772 is designed to elicit both B-cell (antibody) and T-cell immune protection against Streptococcus pneumoniae. ASP3772 includes 24 pneumococcal polysaccharides, as well as two conserved pneumococcal proteins. The results from the Phase II clinical trial demonstrated that ASP3772 was well tolerated. 

  • The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for ASP3772 for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes included in ASP3772 in adults aged 50 years and older. 

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Pneumococcal Infections Current Treatment Patterns

4. Pneumococcal Infections – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Pneumococcal Infections Late Stage Products (Phase-III)

7. Pneumococcal Infections Mid-Stage Products (Phase-II)

8. Pneumococcal Infections Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Pneumococcal Infections Discontinued Products

13. Pneumococcal Infections Product Profiles

14. Key Companies in the Pneumococcal Infections Market

15. Key Products in the Pneumococcal Infections Therapeutics Segment

16. Dormant and Discontinued Products

17. Pneumococcal Infections Unmet Needs

18. Pneumococcal Infections Future Perspectives

19. Pneumococcal Infections Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Strategies

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles